Bandi e concorsi
Graduatoria finale concorso anno 2017
Progetto
|
Punteggio progetto
|
Punteggio CV e struttura
|
Punteggio finale
|
Liquid biopsy: circulating/serum microRNA as novel non invasive prognostic biomarkers in Diffuse Large-B cell Lymphoma.
|
21
|
7
|
28
|
Transferrin Receptor 2 in Myelodysplastic Syndromes: beyond iron metabolism regulation.
|
16
|
12.9
|
28.9
|
Notch-ligand alterations in chronic lymphocytic leukemia: improving biological characterization
and targeted therapies.
|
16
|
11.2
|
27.2
|
Platelet dysfunction caused by ibrutinib and new generation Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukemia: identification of patients at high risk of bleeding and potential reversal by desmopressin administration.
|
25
|
11.3
|
36.3
|
Effect of immunomodulatory drugs on antigen presenting cells: a possible mechanism to increase the allo-reactivity in multiple myeloma patients.
|
20
|
10
|
30
|
Circulating tumor DNA to monitor minimal residual disease in a prospective, multicenter, Fondazione Italiana Linfomi (FIL) study for DLBCL.
|
21
|
14.1
|
35.1
|
Use of blood platelets as siRNA vectors for silencing the bcr-abl fusion gene in Chronic Myeloid Leukemia (CML): in vivo application.
|
17
|
10.2
|
27.2
|
Exploring the role of pre B cell leukemia homeobox 1 (Pbx1) in myeloproliferative neoplasms.
|
26
|
10.3
|
36.3
|
Off-targets effects of Tyrosine Kinase Inhibitors on Dendritic Cells in patients with Chronic Myeloid Leukemia.
|
10
|
9.9
|
19.9
|
Bone marrow mesenchymal stem cell in lymphomas.
|
10
|
8
|
18
|
Graduatoria finale Borsa di Studio 2017
Due progetti hanno ottenuto identico punteggio finale, ma il progetto “Exploring the role of pre B cell leukemia homeobox 1 (Pbx1) in myeloproliferative neoplasms” è risultato vincitore avendo ricevuto una valutazione di merito superiore al progetto “Platelet dysfunction caused by ibrutinib and new generation Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukemia: identification of patients at high risk of bleeding and potential reversal by desmopressin administration”.
Rispetto a questa graduatoria sono ammessi ricorsi entro 3 giorni dalla pubblicazione della stessa sul sito ufficiale dell’associazione.
I commenti sono disabilitati.
|